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a  b s  t r a  c t
The Global Burden of Disease (GBD) study measures the health of populations worldwide
and  by country on an annual basis and aims at helping guide public policy on health issues.
The  GBD estimates for Spain in 2016 and recent trends in mortality and morbidity from 2006
to  2016 were recently published. According to these estimates, chronic kidney disease was
the 8th cause of death in Spain in 2016. Among the top ten  causes of death, chronic kidney
disease was the fastest growing from 2006 to 2016, after Alzheimer disease. At the  current
pace  of growth, chronic kidney disease is set to become the second cause of death in Spain,
after  Alzheimer disease, by  2100. Additionally, among major causes of death, chronic kidney
disease also ranked second only to Alzheimer as  the  fastest growing cause of Years Lived
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with Disability (YLDs) and Disability Adjusted Life Years (DALYs). Public resources devoted
to  prevention, care and research on kidney disease should be in line with both its  current
and future burden.
©  2018 Sociedad Espan˜ola de  Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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r  e s u m  e n
El estudio Global Burden of Disease (GBD) mide la salud de las poblaciones en todo el  mundo
y  en cada país de forma annual, y  tiene como objetivo ayudar a  orientar las políticas públicas
sobre  cuestiones de  salud. Recientemente se publicaron las estimaciones GBD 2016 para
Espan˜a y  las tendencias recientes en mortalidad y  morbilidad de  2006 a  2016. Según estas
estimaciones, la enfermedad renal crónica fue  la octava causa de muerte en Espan˜a en 2016.
Entre las 10 principales causas de muerte, la enfermedad renal crónica fue  la que más  creció
entre 2006 y  2016, después de  la enfermedad de  Alzheimer. Al ritmo actual de crecimiento, la
enfermedad renal crónica se convertirá en la segunda causa de muerte en Espan˜a, después
del  Alzheimer, hacia el 2100. Además, entre las principales causas de muerte, la enfermedad
renal crónica también ocupa el segundo lugar después del Alzheimer como la que más  creció
en an˜os vividos con discapacidad (AVD) y  en an˜os de vida ajustados por discapacidad (AVAD).
Los  recursos públicos dedicados a  la prevención, atención e investigación de la enfermedad
renal deberían estar en línea con su  carga actual y  futura.
©  2018 Sociedad Espan˜ola de  Nefrologı´a. Publicado por  Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Chronic  kidney  disease:  beyond  dialysis,
transplantation  and  chronic  renal  insufficiency
The term kidney disease rapidly evokes the concepts of dial-
ysis and transplantation, that is, renal replacement therapy
for end-stage kidney disease. Indeed, the  57,429 persons (i.e.
0.1% of the population) living on dialysis or carrying a  kidney
graft in Spain in 2016 are estimated to consume 2–5% of the
healthcare budget.1,2 Spain is  a world leader in  kidney trans-
plantation and the Organizacion Nacional de Transplantes
(ONT) continuous efforts ensure that this leadership position
is maintained within the evolving public policy and healthcare
frame.3,4 However, the  point should not be missed that renal
replacement therapy signals the failure of the healthcare sys-
tem to prevent progression of kidney disease. In this regard,
emphasis has moved in  recent years to earlier diagnosis of
kidney disease in order to treat early, thus preventing kidney
disease progression and its potentially lethal complications.
One paradigm shift has been coining the  term chronic
kidney disease (CKD). According to  the  2012 KDIGO (Kidney
Disease: Improving Global Outcomes) definition, CKD is diag-
nosed when abnormalities of kidney structure or function are
present for >3 months, with implications for health.5 Thus, the
diagnosis of CKD is  made in the presence for over 3 months
of one marker of kidney damage (albuminuria >30 mg/24 h
or >30 mg/g urinary creatinine; or urine sediment abnormal-
ities; or electrolyte and other abnormalities due to tubular
disorders; or  abnormalities detected by histology; or struc-
tural abnormalities detected by imaging; or history of kidney
transplantation) or a  decreased glomerular filtration rate (GFR;
GFR <60 ml/min/1.73 m2, GFR categories G3–G5). In this regard,
the CKD concept expands the prior concept of chronic kidney
insufficiency that refers to kidney damage that has resulted
in an (unspecified) decrease in GFR. CKD without renal insuf-
ficiency can now be diagnosed solely based on urinary albumin
values. The immediate clinical implication is  that in the
absence of albuminuria assessment, CKD cannot be ruled out.
This clearly expands the pool of undiagnosed CKD, since in
primary care, albuminuria assessment is restricted to a  few
clinical situations (e.g. diabetes) and even for those situations,
uptake by physicians is  not universal. The KDIGO CKD concept
also provides specific thresholds for eGFR and albuminuria
that allow the diagnosis and categorization of CKD. And now
comes the most interesting part of the  CKD concept: these
thresholds are based on epidemiological studies involving mil-
lions of individuals that indicate that the thresholds mark an
increased risk not only of CKD progression to advanced stages,
but also of all-cause and cardiovascular death, as well as of
acute kidney injury.
Thus, the  57,429 Spanish persons on renal replacement
therapy are only the  tip of the iceberg of the healthcare con-
sequences of kidney diseases. Over 4 million Spaniards (just
over 10% of the adult population based on a  recent SENEFRO
study) have CKD and are at risk of premature death because
of it.6 However, for many or even most of them, neither the
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Table 1 – Leading causes of death in  Spain in 2016 according to GBD and according to INE. The only major difference is
in bold and underlined. INE  (Instituto Nacional de Estadística) data were recorded from Basic cause of death statistics.17
(A) Leading causes of death in Spain in 2016  according to GBD 2016
1. Ischemic heart disease
2. Alzheimer disease
3. Stroke
4. COPD
5. Lung cancer
6. Colorectal cancer
7.  Lower respiratory infection
8. Chronic kidney disease
9. Other cardiovascular
10. Diabetes
(B) Leading causes of death in Spain in 2016 according to  INE, simplified view focused on specific disorders.
Reference to other “other conditions” removed or associated to main condition based on similarity (e.g. other ischemic heart diseases and
acute myocardial infarction were both included under ischemic heart disease), in an  attempt to more closely reflect GBD 2016 methods.
Note the absence of chronic kidney disease from the top ten causes of death.
1. Ischemic heart disease
2. Cerebrovascular disease
3. Lung cancer
4. Heart failure
5. Chronic diseases of  the lower respiratory tract
6. Alzheimer
7. Arterial hypertensive diseases
8. Colon cancer
9. Diabetes mellitus
10. Pneumonia
(C) Leading causes of death in  Spain  in  2016 according to  INE (original INE list of major causes of death)
Note that the concept of chronic kidney disease is not even present in the list.
1. Cerebrovascular diseases
2. Other heart diseases
3. Malignant tumor of  the trachea, bronchial tube and lungs
4. Organic, senile  and presenile mental disorders
5. Other diseases of the respiratory system
6. Heart failure
7. Other ischemic heart diseases
8. Acute myocardial infarction
9. Alzheimer’s disease
10. Chronic diseases of the  lower  respiratory tracts (except Asthma)
11. Hypertension diseases
12. Other diseases of  the  digestive system
13. Malignant tumor of the colon
14. Other diseases of  the  nervous system  and  sensory organs
15. Diabetes mellitus
16. Pneumonia
17. Diseases of the kidney and of the ureter
patient, nor the physician is aware of the CKD diagnosis. It is
thus estimated that the main impact of CKD is not what we
see (persons on renal replacement therapy) but what we do
not see (premature deaths, even before reaching the need for
renal replacement therapy). In this regard, CKD is not usually
listed as a cause of death in CKD patients who die prematurely
because of  the negative impact of CKD on different organs and
systems. The Global Burden of Disease study is addressing
such inconsistencies in the attributable cause of death on a
worldwide basis and for over 200 causes of death.
What  is  the  GBD  study?
The Global Burden of Disease (GBD) initiative of the  Institute
for Health Metrics and Evaluation (IHME) at the University of
Washington measures the health of populations worldwide
on an  annual basis.7 GBD produces age-, sex-, and country-
specific health estimates using highly standardized, validated
approaches applied to all available data sources and adjusted
for major sources of bias, so as  worldwide results are  com-
parable. The GBD  2016 report was published in  September
2017.8–12 The recent publication of the country-specific GBD
2016 report provides interesting insights into the current and
future burden of CKD in Spain.13
How  does  the  GBD  study  attribute  the  cause
of  death?
The GBD assess cause of death worldwide using a  uni-
form methodology that has  been extensively detailed in
GBD publications.11,14 Specifically, it relies on robust statisti-
cal methods including the Cause of Death Ensemble model
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(CODEm) to generate estimates for each location, year, age,
and sex. For GBD, each death is attributed to a single under-
lying cause – the cause that initiated the series of events
leading to death – in accordance with International Classifi-
cation of Diseases (ICD) principles.11 The GBD  cause of death
list is organized as a  hierarchy, with each level composed of
causes of death that are mutually exclusive and collectively
exhaustive. For GBD 2016, separate estimates were developed
for a total of 264 unique causes and cause aggregates. Mul-
tiple sources of data are, for Spain the main source is the
Mortality Information System INEbase of the Spanish National
Institute of Statistics (INE). Cause of death data are then stan-
dardized and processed in a  uniform manner. This includes
identifying and redistributing deaths assigned to ICD codes
that cannot be underlying causes of death; are intermediate
causes of death rather than the underlying cause (e.g., sepsis
and heart failure); or lack specificity in coding. These so-called
garbage codes are redistributed using the GBD method: deaths
coded in this manner were reassigned to  likely causes of death
using different approaches.14
What  did  the  GBD  2016  report  for  Spain  say
about  CKD?
According to GBD 2016 estimates, CKD was the 8th cause of
death in Spain in 2016 (Table 1A).13 Among the  top ten causes
of death, CKD was the fastest growing from 2006 to 2016, after
Alzheimer disease (Fig. 1A). Additionally, among the top ten
causes of death, it also ranked second only to  Alzheimer as
the fastest growing cause of Years Lived with Disability (YLDs)
(Fig. 1B) and Disability Adjusted Life Years (DALYs) (Fig. 1C).
DALYs are the sum of years of potential life lost due to  pre-
mature mortality and the  years of productive life lost due to
disability. At the current pace, CKD is set to become the second
most frequent cause of death in Spain by 2100, after Alzheimer
disease (Fig. 2).
What  was  known  about  CKD mortality  in  Spain
until  now?
The main source of health information in Spain is the INE,
which is used to guide public policy.15 We  grouped INE causes
of death into a simplified view, aiming at using the same broad
concepts as in GBD 2016, and identified ten top causes of death
in 2016 according to INE (Table 1B). All categories of cause of
death present in the top ten GBD 2016 list can be recognized
in the INE ranking, with the exception of CKD. For this sim-
plified view of INE data, we did not take into account items
labeled “other”, because of their non-specific nature and for
example, we  grouped “acute myocardial infarction” together
with “other ischemic heart diseases” in  the  same category of
“ischemic heart disease”. Overall, the main difference with
the GBD 2016 ranking is  the presence of hypertension and
the absence of CKD within the top  ten  causes of death in the
simplified INE ranking. The term closest to the CKD concept,
at position eleven (and, thus, not shown in Table 1B) if terms
including “other” are excluded, is a wider category of “diseases
of the kidney and of the ureter”. The fact that one of the top
causes of death, according to the GBD 2016 methodology, is
Fig. 1 – Trends in  top ten causes of death in Spain,
2006–2016. The top ten causes of death in 2016 in Spain
in terms of number of deaths and their impact on YLDs
and DALYs are  shown. (A) % change in number of deaths
2006–2016. (B) %  change in  number of YLDs 2006–2016.
Data for top ten causes of death in  2016 which are also
among the top 30 causes of YLDs are shown. (C)  % change
in number of DALYs 2006–2016. COPD: Chronic Obstructive
Pulmonary Disease; YLDs: Years Lived with Disability;
DALYs: Disability Adjusted Life Years.
hidden from the view of policy makers may  be  considered a
major flaw of the INE information system. This indeed may  be
one of the reasons for the growing impact of CKD on mortal-
ity, since funding for research and early intervention lags well
behind other major causes of death.
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Fig. 2 – Predicted growth of the top eight causes of death from 2016 to 2100 in Spain, based on growth from 2006 to  2016
according to the GBD 2016 study. Alzheimer is predicted to become the most frequent cause of death by  2026 and is not
represented in the graph due to its magnitude, which would preclude appreciating details for the other causes of death. The
2006–2016 change in number of deaths was extrapolated to predict annual number of deaths up to 2100. COPD: Chronic
Obstructive Pulmonary Disease; YLDs: Years Lived with Disability; DALYs: Disability Adjusted Life Years.
Why  GBD  2016  and  INE  data  do  not  match?
Spain GBD 2016 manuscript emphasized discrepancies
between causes of death for Spain GBD 2016 and data from the
INE that may  impact public health policy planning.13 The dis-
crepancies between INE and GBD may  depend on the  different
definitions used. INE statistics follow the ICD-10 cause of death
list. In this regard, several GBD 2016 and INE definitions differ.
As examples, IHD is represented by two different categories
in INE, “Acute myocardial infarction” and “Other ischemic
heart diseases”. Hypertension is considered a garbage code
in GBD and is  redistributed to other causes of death. Several
items labeled “other”, representing several different condi-
tions, made it into the top ten ranking in INE. Overall, all
conditions except one in the top ten causes of death accord-
ing to GBD 2016 can be recognized in a simplified INE list
(Table 1B), the sole exception being CKD. However, the origi-
nal ICD-10-based INE rankings differ more  from GBD 2016 data
(Table 1C). This may  reflect the absence of CKD from the ICD-
10 cause-of-death lists as per guidance from the US Centers
For Disease Control And Prevention (CDC),16 where the clos-
est term, included within “diseases of the kidney and of the
ureter”, is kidney failure. Kidney failure, according to the cur-
rent consensus international KDIGO 2012 definition, is applied
to those on or needing renal replacement therapy, and not
to the wider CKD population. Additionally, GBD redistributes
causes of death, so the called garbage codes, as explained
above, based on a  complex algorithm that takes into account
an updated medical literature.11,14
Is  Spain  different  from  other  countries  in terms
of the  impact  of  CKD  in mortality?
Not really. According to GBD 2016, CKD was  the 10th most
frequent cause of death worldwide when assessed by the
age-standardized death rate per 100,000, and together with
Alzheimer and diabetes, it was among the three fastest grow-
ing causes of number of deaths or of age-standardized death
rates, and the second fastest growing after Alzheimer in
terms of YLL.11 Indeed, the CKD age-standardized death rate
increased by 28.8% and the YLLs by 21% from 2006 to 2016 on
a worldwide basis.
A  dynamic  versus  a static  view
In conclusion, the  recently published GBD  2016 Spain study
should be a  call to action for the medical community, health-
care authorities and the  population at large. CKD lags well
behind other major causes of death in terms of resources
devoted to prevention, early therapy and research. Public
resources devoted to prevention, care and research on kidney
disease should be  in line with both its current and future bur-
den. Without a significant increase in  funding for such activity
that dramatically changes the 2006–2016 trend, CKD is set to
become the second cause of death in Spain for future genera-
tions. GBD 2016 data, by providing a time series over the years,
evaluated with the same methodology, standardized and con-
sistent with the methods applied to other countries, provides
a  dynamic view of the evolving health landscape in Spain that
allows planning for the future based on worrisome secular
trends like the unrelenting rise of CKD as  a  major cause of
death.
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